compound 13c [PMID: 20684591]   Click here for help

GtoPdb Ligand ID: 9681

Compound class: Synthetic organic
Comment: Compound 13c [PMID: 20684591] is a potent, orally active and competitive inhibitor of all three isoforms of protein kinase D [2]. It is one of the chemical structures claimed in Novartis' patent WO2008122615 [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 65.97
Molecular weight 388.24
XLogP 4.22
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1CCC(CC1)Nc1nccc(c1)c1cc2cnccc2c(n1)N1CCNCC1
Isomeric SMILES C1CCC(CC1)Nc1nccc(c1)c1cc2cnccc2c(n1)N1CCNCC1
InChI InChI=1S/C23H28N6/c1-2-4-19(5-3-1)27-22-15-17(6-9-26-22)21-14-18-16-25-8-7-20(18)23(28-21)29-12-10-24-11-13-29/h6-9,14-16,19,24H,1-5,10-13H2,(H,26,27)
InChI Key DIZACSOTRSXCHC-UHFFFAOYSA-N
References
1. Dobler MR, Jewell CF Jr, Meredith E, Monovich LG, Siska S, Von MA, Van EM, Yoon T, Gaul C, Capparelli MP. (2008)
[2, 6] naphthyridines useful as protein kinase inhibitors.
Patent number: WO2008122615. Assignee: Novartis Ag. Priority date: 06/04/2007. Publication date: 04/04/2008.
2. Meredith EL, Ardayfio O, Beattie K, Dobler MR, Enyedy I, Gaul C, Hosagrahara V, Jewell C, Koch K, Lee W et al.. (2010)
Identification of orally available naphthyridine protein kinase D inhibitors.
J Med Chem, 53 (15): 5400-21. [PMID:20684591]